New hope for Parkinson's drooling: drug trial shows promise
NCT ID NCT06319118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether dihydroergotine mesylate extended-release tablets can reduce drooling in people with Parkinson's disease. 120 patients took either the drug or a placebo for 12 weeks. Researchers measured changes in saliva weight and also looked at effects on thinking skills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dihydroergotine mesylate extended-release tablets
What this could lead to
If it works, this could provide a new option to reduce drooling and possibly improve cognitive function in people with Parkinson's disease.
What could go wrong
This is a small, completed phase 4 trial with only 120 participants. The results may not apply to all Parkinson's patients, and the drug may cause side effects or fail to show a meaningful benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Arilliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China